about
Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life OutcomesThrombocytopenia and hemorrhagic risk in cancer patients.Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience.Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.A case of transplantation-associated thrombotic microangiopathy with cardiac involvement successfully treated with plasma exchangeFront-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance.Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom's macroglobulinemia: a retrospective multicentric studyTriazene compounds: mechanism of action and related DNA repair systems.Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: a concise review.Pathogenetic, Clinical, and Prognostic Features of Adult t(4;11)(q21;q23)/MLL-AF4 Positive B-Cell Acute Lymphoblastic Leukemia.Tuberculous meningoencephalitis in a patient with hairy cell leukemia in complete remission.The interferons in haematological malignancies.Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6.Statins may potentiate bisphosphonates anticancer properties: a new pharmacological approach?What is the best treatment for acute promyelocytic leukemia?The role of biotherapies (interleukins, interferons and erythropoietin) in multiple myeloma.Foetal haemoglobin, erythrocytes containing foetal haemoglobin, and hematological features in congolese patients with sickle cell anaemia.High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network.High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.The potential role of pre-transplant HBcIgG seroposivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: a study from the Rome Transplant Network.Intraventricular thrombosis during all-trans retinoic acid treatment in acute promyelocytic leukemia.Prevention of delayed emesis induced by moderately emetogenic chemotherapy in patients with acute emesis: a pilot study with ACTH-Depot plus tropisetron.Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem.A retrospective study on 73 elderly patients (≥75years) with aggressive B-cell non Hodgkin lymphoma: clinical significance of treatment intensity and comprehensive geriatric assessment.Raltitrexed as monochemotherapy induces a statistically significant increase in platelet count.Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience.Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol.Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols.Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cells in patients with multiple myeloma.Recurrent thrombophlebitis in a colon cancer patient with C677T heterozygous genotype for MTHFR treated with 5-fluorouracil-based adjuvant chemotherapy.Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis.In situ electrostimulation drives a regenerative shift in the zone of infarcted myocardium.Contact activation and factor VII after the use of an activated prothrombin complex concentrate (FEIBA) in hemophiliacs with inhibitors.Thrombophilic screening in young patients (< 40 years) with idiopathic ischemic stroke: a controlled study.The combination topotecan, temozolomide and dexamethasone associated with radiotherapy as treatment of central nervous system myeloma relapse.Relapse of IgA lambda multiple myeloma presenting as obstructive jaundice and abdominal pain.A mocking finding: portal cavernoma mimicking neoplastic mass. First sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation.BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results.
P50
Q23671265-943AF606-2912-4C4C-B3D7-74C150B1E4AEQ33357171-D67E4FB3-EFA5-47A3-B592-62CA8F014301Q33373150-99159EDF-0BCB-43C6-9C2B-3BF565F5F928Q33409020-6DD6648A-B411-45B6-A531-1BD731E7C8E4Q33501152-B1B9A7C9-73A1-4847-A0B5-02B0C8FCE559Q34316427-0C909D1E-4B32-4192-9BE6-7470C96D77FDQ34621685-F5A67AB9-7EC7-4B39-B1A3-F2DFE42807ABQ34985781-583B79D6-7606-4FE2-AF38-3103DF4F1299Q35865686-7C56D2F1-1546-4DCA-AA0A-D0E6873A852BQ36952877-A3AAFE1D-E35C-4E0C-BCA8-9886C990E4D1Q37814684-9C3898A6-C10B-4147-A1F1-AE0C35413CD6Q37970679-ABE2D565-EC71-4FBF-A6C5-5DEAF776B51BQ40283234-DFB518B0-8571-4A58-96C3-FC02A6C129B4Q40390982-F81F13E5-ECCC-4D35-9CE2-FA186861B62DQ40544788-2AE516C2-98E4-4A83-82D2-68E32518DB6BQ40584452-6BC060A8-ACE5-4993-9089-6929490EB3B0Q40722987-613EF762-9CF6-49D9-A198-7B41886601D8Q41142659-41F5DF1D-41CA-471E-8941-8FBCA10ED44AQ42051343-A3B0A6A3-122D-45B4-98F6-28DC45FFD610Q42256487-799B5184-BB2B-4603-B2EA-0D89B9BE2DB1Q43274038-C20C32F5-8876-424A-A39C-678611A2E718Q43445569-6A54B561-21F5-45FA-9AF7-787BAFCC83B7Q43692584-E2EB311E-A990-46B1-B967-FC044CD5348DQ43846165-0690DC11-4890-4056-A269-43F77019DE24Q43863897-92208B83-CD70-49DF-A0C0-D9AC0E42DEC3Q44079539-FC06598F-2554-4B6B-BB5C-816D25F421E6Q44114212-7FDCDD28-25CE-4666-8364-B6A20235389BQ44117619-9DF511BF-C4C4-4EF2-A2CF-695EECB0F518Q44194162-AD0818F6-7959-4ACC-A049-D5C0FA02E937Q44452171-545C7435-B4A8-4692-AE8A-E39557AA1B95Q44508563-16394C8A-A473-4B1D-A5C4-27973CF15849Q45081601-4C9CDBFB-E5C0-42E6-A404-7C365137EE4DQ45196348-74F5B104-9527-4798-89E3-9C8B89F6F367Q45826779-34040D40-7827-4C48-AD82-1838F2767B97Q45857486-57C587DD-C5ED-41CC-95E9-04196629D318Q46061041-6DD58C7B-FFA1-4687-9CED-F60B9141F1EDQ46074328-562AC144-1076-4088-A5D4-6A2B70723E7FQ46084286-8798120A-DDA4-48D1-9B60-A9A686DAA058Q46124340-FAC194DB-99CF-4831-B01E-47929F1E2EC1Q46478244-3643D249-AAF4-4FB5-900A-43520EED4A6F
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Giuseppe Avvisati
@ast
Giuseppe Avvisati
@en
Giuseppe Avvisati
@es
Giuseppe Avvisati
@nl
Giuseppe Avvisati
@sl
type
label
Giuseppe Avvisati
@ast
Giuseppe Avvisati
@en
Giuseppe Avvisati
@es
Giuseppe Avvisati
@nl
Giuseppe Avvisati
@sl
prefLabel
Giuseppe Avvisati
@ast
Giuseppe Avvisati
@en
Giuseppe Avvisati
@es
Giuseppe Avvisati
@nl
Giuseppe Avvisati
@sl
P1006
P214
P1006
P106
P1153
7006993429
P21
P213
0000 0003 8984 3532
P214
P31
P496
0000-0002-5027-5868
P735
P7859
viaf-283319686